# APPLICATION

FOR

UNITED STATES LETTERS PATENT

TITLE: CONTROLLING GENE EXPRESSION IN LIVING CELLS

APPLICANT: MICHAEL R. GREEN AND GEOFF WERSTUCK

CERTIFICATE OF MAILING BY EXPRESS MAIL

Express Mail Label No.____EL485514203US_____

I hereby certify under 37 CFR §1.10 that this correspondence is being deposited with the United States Postal Service as Express Mail Post Office to Addressee with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

_____April 2, 2001_____
Date of Deposit

_____
Signature

_____
Typed or Printed Name of Person Signing Certificate

CONTROLLING GENE EXPRESSION IN LIVING CELLS

Field of the Invention

5   The invention relates to biochemistry, molecular biology, cell biology, medicine, and gene therapy.

Background of the Invention

A method commonly known as "*in vitro* selection" (Ellington et al., *Nature* **346**:818-822 (1990), "*in vitro*

10   evolution" (Joyce, *Gene* **82**:83-87 (1989), or "SELEX" (Selective Evolution of Ligands by Evolution) Tuerk et al., *Science* **249**:505-510 (1990) allows the screening of large random pools of nucleic acid molecules for a particular functionality. This technique has been used to screen for

15   functionalities such as binding to small organic molecules (Famulok et al., *Am. J. Chem. Soc.* **116**:1698-1706 (1994); Connell et al., *Biochemistry* **32**:5497-5502 (1994); Ellington et al., *Nature* **346**:818-822 (1990)), large proteins (Jellinek et al., *Proc. Natl. Acad. Sci. USA* **90**:11227-11231 (1993);

20   Tuerk et al., *Proc. Natl. Acad. Sci. USA* **89**:6988-6992 (1992); Tuerk et al., *Gene* **137**:33-39 (1993); Schneider et al., *J. Mol. Biol.* **228**:862-869 (1992)); and the alteration or *de novo* generation of ribozymes (Liu et al., *Cell* **77**:1093-1100 (1994); Green et al., *Nature* **347**:406-408

25   (1990); Green et al., *Science* **258**:1910-1915 ((1992); Pun et al., *Biochemistry* **31**:3887-3895 (1992); Bartel et al., *Science* **261**:1411-1418 (1993). Functional molecules, known as "aptamers" (from "aptus," Latin for fit) are selected by column chromatograpy or any other technique of enrichment

30   for the desired function.

For *in vitro* selection, a pool of oligonucleotides is synthesized with a completely random base sequence flanked PCR primer binding sites. The pool is subjected to

the enrichment step, and then selected molecules are amplified in a PCR step. Up to 10^{15} different molecules, i.e., every possible permutation of an oligonucleotide containing a 25-base sequence, can be generated in this way

5 and then screened simultaneously. Large numbers of random permutations of longer base sequences can be generated by carrying out the PCR step under mutagenic conditions (Lehman et al., *Nature* **361**:182-185 (1993); Beaudry et al., *Science* **257**:635-641 (1992)).

10 ## Summary of the Invention

We have discovered that aptamers incorporated into an RNA faithfully bind their ligand *in vivo*. Based on this discovery, the invention provides methods for controlling expression of a gene in a living cell. In general, the

15 method includes contacting the 5'untranslated region of an RNA in the cell with a cell permeable, small molecule. In some embodiments of the invention, the method includes providing an aptamer that binds specifically to a cell permeable, small molecule; incorporating the aptamer into a

20 region of a gene, which region encodes a 5' untranslated region (5' UTR) of an RNA; and contacting the cell-permeable, small molecule with a cell that contains the gene. The cell-permeable, small molecule enters the cell and binds specifically to the aptamer sequence in the 5' UTR

25 of RNA molecules transcribed from the gene. This binding specifically inhibits translation of the RNA molecules to which the cell permeable, small molecule is bound, thereby controlling expression of the gene.

The gene whose expression is controlled can be an

30 endogenous gene or a transgene. The cell can be a prokaryotic cell or a eukaryotic cell. In some embodiments,

- 2 -

the eukaryotic cell is a mammalian cell. The mammalian cell
can be *in vivo*, e.g., in a human receiving gene therapy.
The cell permeable molecule can be administered to the
mammal by any suitable route, e.g., topically, parenterally,
5   orally, vaginally, or rectally.

The invention also provides a gene containing an
aptamer sequence incorporated into a region of the gene that
encodes a 5' UTR of an RNA. The invention also provides a
transgenic cell containing an aptamer incorporated into a
10 region of a gene that encodes a 5' UTR of an RNA.
Preferably, the cell includes an RNA transcript containing
the aptamer in the 5' UTR of the RNA transcript. The cell
can contain a cell permeable, small molecule that binds
specifically to the aptamer.

15 The invention also provides a bacterial resistance
marker. The marker includes an aptamer sequence operably
linked to a bacterial expression control sequence.

The invention also provides a method for determining
whether a gene of interest is essential for the survival or
20 growth of a cell. This method is useful in target
validation studies. The method includes structurally
disrupting or deleting an endogenous gene of interest in a
cell; providing an aptamer that binds specifically to a cell
permeable, small molecule; incorporating the aptamer into a
25 region of the gene of interest *in vitro*, which region
encodes a 5' untranslated region of an RNA, thereby
producing a controllable gene of interest; introducing the
controllable gene of interest into the cell, thereby
producing a test cell; and contacting the cell-permeable,
30 small molecule with the test cell, so that the cell-
permeable, small molecule enters the test cell and controls
expression of the controllable gene of interest.

- 3 -

As used herein, "cell permeable, small molecule" means a molecule that permeates a living cell without killing the cell, and whose molecular mass is about 1,000 Daltons or less.

5   Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In case of conflict, the present application, including definitions will control.

10   All publications, patents, and other references mentioned herein are incorporated by reference.

Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and

15   materials are described below. The materials, methods, and examples are illustrative only and not intended to be limiting. Other features and advantages of the invention will be apparent from the detailed description, and from the claims.

20   **Brief Description of the Drawings**

Fig. 1 is a tobramycin-binding consensus aptamer nucleic acid sequence, with predicted secondary structure indicated.

Fig. 2 is a kanamycin A-binding consensus aptamer

25   nucleic acid sequence, with predicted secondary structure indicated.

Figs. 3A-3E are growth curves of *E. coli* expressing antibiotic aptamers. Overnight cultures of BL-21 cells transformed with plasmids expressing RSETA, tob1, tob3, kan1

30   or kan3 were diluted 100-fold into medium containing the indicated concentration of aminoglycoside antibiotic. Optical density (660 nm) was measured at fixed intervals

- 4 -

over 8 hours of growth at 37°C. Fig. 3A shows data on bacterial growth in the absence of drug. Fig. 3B shows data on bacterial growth in the presence of 10 µM Kanamycin A. Fig. 3C shows bacterial growth in the presence of 10 µM
5   Tobramycin. Fig. 3D shows growth in the presence of 20 µM Kanamycin A. Fig. 3E shows bacterial growth in the presence of 20 µM Tobramycin.

Fig. 4. is a histogram showing percent translation of mRNA in a wheat germ *in vitro* translation system
10   containing 0 (RSETA) or 3 copies of the tob aptamer cloned into the 5' UTR of RSETA (tob3-RSETA) and 0, 30 or 60 µM tobramycin or kanamycin A. Protein products were analyzed by SDS-PAGE and quantitated by densitometry. For each transcript, translation in the absence of drug was set at
15   100%.

Fig. 5 is the chemical structure of Hoescht Dye H33258.

Fig. 6 is the chemical structure of Hoescht Dye H33342.

20   Fig. 7 is the nucleotide sequence and predicted secondary structure of H33258 aptamer H10, based upon the computer modeling program Mulfold. A Hoescht dye aptamer consensus sequence (UUAN$_{4-5}$UCU) was identified after 10 rounds of selection. The fixed primer binding regions are
25   shown in plain print, selected bases are in bold, and the selected consensus sequence is indicated by outline print.

Fig. 8 is the nucleotide sequence and predicted secondary structure of H33258 aptamer H19, based upon the computer modeling program Mulfold.
30   Fig. 9 is a histogram summarizing data on the interaction of H10 and H19 aptamers with H33258, as indicated by percentage of total bound RNA eluted from an affinity column. Labeled aptamer (200,000 cpm of ^{32}P-UTP)

- 5 -

was loaded onto a 0.25 ml H33258-Sepharose column. Each column was then washed sequentially with 6 ml binding buffer, 1 ml binding buffer containing 5 mM H33258, and 1 ml binding buffer containing 25 mM H33258. Fractions were

5 collected and quantitated by scintillation counting.

Fig. 10. is a histogram summarizing SDS-PAGE densitometry data from *in vitro* translation experiments. RNA transcripts containing 0 (RSETA) or 2 copies of an H33258 aptamer (H2-RSETA) were translated in a wheat germ

10 extract in the presence of ^{35}S-methionine and 0, 40 or 80 μM H33258. Protein products were subjected to SDS-PAGE and quantitated by densitometry. For each transcript, translation in the absence of drug was set at 100%.

Fig. 11 is a histogram summarizing data from *in vivo*

15 expression experiments. H33258 aptamers H10 and H19 were cloned in tandem into the 5' UTR of a β-galactosidase reporter gene (SVβgal; Promega) to generate SVH2βgal. CHO cells were cotransfected with 1 μg SVβgal or SVH2βgal and 1 μg of a luciferase expression vector (pGL3). Transfected

20 cells were grown in the presence of 0, 5, or 10 mM H33342. Twenty-four hours after transfection, cell extracts were prepared, and β-galactosidase and luciferase activities were determined.

Detailed Description

25 **Providing an Aptamer**

Techniques for *in vitro* selection of aptamers that bind specifically to a particular cell-permeable molecule, i.e., ligand, are known in the art. Those techniques can be employed routinely to obtain an essentially unlimited number

30 of apatmers useful in the present invention. Examples of publications containing useful information on *in vitro* selection of aptamers include the following: Klug et al.,

- 6 -

Molecular Biology Reports **20**:97-107 (1994); Wallis et al., *Chem. Biol.* **2**:543-552 (1995); Ellington, *Curr. Biol.* **4**:427-429 (1994); Lato et al., *Chem. Biol.* **2**:291-303 (1995); Conrad et al., *Mol. Div.* **1**:69-78 (1995); and Uphoff et al.,
5   *Curr. Opin. Struct. Biol.* **6**:281-287 (1996).

The basic steps in conventional *in vitro* selection of an aptamer are as follows. A random DNA pool is synthesized, i.e., a pool of DNA molecules having random nucleotide sequences. The random DNA pool is transcribed to
10   produce a random RNA pool. The RNA pool is subjected to affinity chromatography. RNA molecules that bind specifically to the immobilized ligand are collected and reverse-transcribed into cDNA and amplified by PCR. The PCR-amplified products are transcribed into RNA. The
15   process is repeated for as many cycles as necessary to yield a population of nucleic acid molecules that bind to the ligand with the desired affinity (and specificity). Individual nucleic acid molecules from the selected population are cloned and sequenced using conventional
20   recombinant DNA technology. Such technology is described in numerous references, e.g., Sambrook et al., *Molecular Cloning - A Laboratory Manual* (2nd ed.), Cold Spring Harbor Laboratory Press (1989).

For any given cell permeable, small molecule
25   (ligand), a potentially large number of different, useful aptamers can be isolated by one of ordinary skill in the art, using conventional techniques, without undue experimentation. The aptamers are empirically selected from a random pool of nucleic acid molecules by predictable
30   selection methods. Therefore, it is not necessary to know in advance of the selection process what the nucleotide sequence of the aptamer will be.

The optimal length of the random nucleotide sequence in the aptamer length will vary, depending on factors including the size and shape of the ligand. Preferably, the length of an aptamer used in this invention is between 10
5   and 200 nucleotides. More preferably, the length is between 20 and 100 nucleotides.

Among the numerous aptamer-ligand pairs useful in this invention, aptamer-ligand binding affinities can vary widely. In general, the affinity is high enough to provide
10 effective control of gene expression, but not so high as to make the aptamer-ligand binding effectively irreversible. Determination of whether a particular aptamer-ligand pair displays a suitable binding affinity is within ordinary skill in the art.

15 **Incorporating the Aptamer**

After isolation of an aptamer that binds the cell permeable molecule (ligand) with suitable affinity and specificity, the aptamer is incorporated into the 5' UTR of a gene whose expression is to be controlled. The
20 incorporation can be carried out, without undue experimentation, using conventional recombinant DNA technology.

The gene whose expression is to be controlled can be an endogenous gene or a transgene. When the gene is an
25 endogenous gene, the aptamer can be incorporated into the 5' UTR by known techniques of gene targeting, i.e., homologous recombination. When the gene is a transgene, preferably the aptamer is incorporated into the 5' UTR by *in vitro* manipulation of the transgene or a DNA vector containing the
30 transgene.

A gene controlled according to this invention can be in a prokaryote or a eukaryote. The gene can be in an

- 8 -

episome, e.g., a plasmid, or a genome, e.g., a mammalian chromosome. A transgene or gene targeting vector can be introduced into the living cell (that will be contacted with the cell permeable molecule), or a progenitor of the cell,

5   by any suitable means. The suitable means will depend, at least in part, on the identity of the living cell. This is illustrated by the following non-limiting examples. If the living cell is a yeast cell, the transgene or gene targeting vector can be electroporated directly into the yeast cell or

10   a progenitor of the yeast cell. If the cell is in a transgenic plant, the transgene or gene targeting vector can be introduced into regenerable plant tissue culture cells by electroporation, ti-plasmid, or microparticle bombardment. If the living cell is a cell in a transgenic, non-human

15   mammal, the transgene or gene targeting vector can be microinjected into an embryonic cell that is used to produce the non-human mammal. If the cell is *in vivo* in a human receiving gene therapy, the transgene or gene targeting vector can be introduced into target cells of the human by

20   any suitable gene therapy technique, e.g., a viral vector or injection of naked DNA.

Cell Permeable, Small Molecule

There is wide latitude in the choice of the cell permeable, small molecule used in this invention. The cell

25   permeable, small molecule must bind an aptamer with suitable affinity and specificity. Whether a molecule will bind an aptamer with suitable affinity and specificity depends on factors including molecular size, shape and charge. Those of skill in the art will appreciate that the cell permeable

30   molecule can be chosen first, and then used for *in vitro* selection of an aptamer that binds to it. Choosing a cell permeable, small molecule that is suitable for use in *in*

- 9 -

vitro selection of an aptamer is within ordinary skill in the art.

Preferably, the cell permeable, small molecule displays low toxicity, so that unwanted biological side effects are minimized. When the cell containing the gene to be controlled is *in vivo*, the cell permeable, small molecule is chosen to have an *in vivo* persistence sufficient to allow an effective amount of the cell permeable, small molecule to reach and enter the cell.

In some embodiments of the invention the cell permeable, small molecule is a drug previously approved for use in humans. Using an approved drug can be advantageous, because information on safety, side effects, dosage, route of administration, pharmacokinetics, metabolism, clearance and other useful information is available. Preferred drugs are those that display mild pharmacological activities and minimal side effects.

It is not necessary, however, for the cell permeable, small molecule to be a drug. In preferred embodiments of the invention, the cell permeable, small molecule is pharmacologically inert (except for its activity in binding the aptamer according to this invention). Preferably, the cell permeable, small molecule is an organic compound. The design and synthesis of small, organic, cell permeable molecules useful in this invention are described, for example, in Amara et al., *Proc. Natl. Acad. Sci. USA* 94:10618-10623 (1997); and Keenan et al., *Bioorganic & Medicinal Chemistry* 6:1309-1335 (1998).

Formulating and Administering the
Cell Permeable, Small Molecule

The cell permeable, small molecule can be formulated, individually or in combination, into

pharmaceutical compositions by admixture with pharmaceutically acceptable nontoxic exipients and carriers. Such compositions can be prepared for use in parenteral administration, particularly in the form of liquid solutions

5 or suspensions; for oral administration, particularly in the form of liquid, tablets or capsules; or intranasally, particularly in the form of powders, nasal drops, or aerosols.

The composition can be administered conveniently in

10 unit dosage form and can be prepared by any of the methods known in the art. Such methods are described, for example, in *Remington's Pharmaceutical Sciences* (Mack Pub. Co., Easton, Pa., 1980).

Liquid dosage forms for oral administration include

15 pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active compound, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and

20 emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol,

25 tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.

30 Injectable depot forms are made by forming microencapusule matrices of the drug in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of drug to polymer and the nature of the

- 11 -

particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides) Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissues.

Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, 3) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.

The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings

- 12 -

and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only,

5   or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes.

Solid compositions of a similar type may also be

10   employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.

The active compounds can also be in micro-encapsulated form with one or more excipients as noted

15   above. In solid dosage forms the active compound may be admixed with at least one inert diluent such as sucrose, lactose or starch. Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting

20   aids such a magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only,

25   or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes.

Target Validation

30   The present invention can be used in "target validation" studies. The goal of target validation is to determine whether a particular gene is essential for the

- 13 -

survival or growth of a particular type of cell, e.g., a
bacterial pathogen. If a gene of interest is an essential
gene, it (or its expression product) constitutes a potential
drug target, which can be used for drug screening or
5   rational drug design.

Target validation technology has previously relied
on a conventional gene "knockout" approach. See, e.g.,
Arigoni et al., *Nature Biotechnology* **16**:851-856 (1998). A
disadvantage of the conventional gene knockout approach is
10   that the gene is either present or absent, i.e.,
intermediate levels of expression of the gene of interest
are not evaluated.

The present invention advantageously allows
measurement of the effect of intermediate levels of
15   expression of the gene of interest. For example, a 50%
reduction in expression of an essential gene might be
sufficient to cause the death of a microbial pathogen. Such
information, now can be obtained readily through the use of
this invention.

20   **Examples**

The invention is further illustrated by the
following examples. The examples are provided for
illustration purposes only, and are not to be construed as
limiting the scope or content of the invention in any way.
25   We demonstrated that bacteria expressing an aptamer
to an aminoglycoside antibiotic are resistant to the cognate
drug. This indicated that a small molecule-aptamer
interaction occured *in vivo*. To regulate gene expression,
aminoglycoside aptamers were inserted into the 5' UTR of an
30   mRNA, whose *in vitro* translation then became repressible by
drug addition. To determine if a similar approach could
work *in vivo*, we derived RNA aptamers for cell-permeable

- 14 -

Hoechst dyes and inserted them into the 5'UTR of a β-galactosidase reporter gene. Following transfection into mammalian cells, expression of the reporter gene was specifically inhibited by drug addition.

5   An initial 70 nucleotide RNA pool containing 31 random nucleotides was constructed essentially as described by Singh et al., *Science* **268**:1173 (1995). Tobramycin or kanamycin A were covalently linked to CNBr-activated Sepharose 4B. Aminoglycosides (2 mmoles) were dissolved in

10   coupling buffer (0.1 M NaHCO$_3$, 0.5 M NaCl, pH 8.3), then mixed with CNBr-activated Sepharose 4B (preswollen in 1 mM HCl) and incubated at 4°C for 12-16 hours. The resin was then washed and remaining active groups blocked with 0.2 M glycine. Pre-selection columns were prepared with glycine

15   alone.

The RNA pool (approximately 10^{15} individual sequences) was dissolved in selection buffer (50 mM Tris, pH 8.3, 250 mM KCl, 2 mM MgCl$_2$) heated to 80°C for 3 minutes and cooled to room temperature. RNA was then loaded onto a

20   pre-selection column (0.25 ml glycine-Sepharose) to remove RNAs that bound to the column, the resin, or glycine. Non-binding RNAs were eluted with two column volumes of selection buffer and immediately loaded onto a 0.5 ml aminoglycoside-Sepharose column. Columns were washed with

25   10 column volumes of selection buffer (selection rounds 1-5), 10 column volumes buffer with 5 mM competitor aminoglycoside (rounds 6-9), or 10 column volumes buffer with 10 mM competitor (rounds 10-14). The competitor aminoglycoside for tobramycin aptamer selection was

30   kanamycin A and vice versa. In each round, bound RNA was eluted with 5 mM of the cognate aminoglycoside.

Eluted RNA was RT-PCR amplified using flanking primers. The PCR products were transcribed into RNA with T7

RNA polymerase and purified by polyacrylamide gel
electrophoresis. Pools were subcloned into the plasmid
pBlueScript (Stratagene) and sequenced after rounds 10, 12,
and 14. Isolation of H33258 aptamers was carried out in a
5   similar manner, with the following exceptions. H33258 was
covalently linked to epoxy-activated Sepharose 6B. The
ligand solution was mixed at 37°C for 16 hours. The resin
was then washed and excess active groups were blocked with 1
M ethanolamine (pH 10). Pre-selection columns were prepared
10   with ethanolamine alone. H33258 selection buffer contained
50 mM Tris pH 7.3, 200 mM KCl, 2mM $MgCl_2$.

In selection rounds 1-6, columns were washed with 20
column volumes of selection buffer and eluted with 2 column
volumes of 10 mM H33258. In selection rounds 7-10, columns
15   were washed with 20 column volumes buffer and 20 column
volumes 10 mM benzimidazolepropionic acid (in selection
buffer) before elution.

Fig. 1A shows the consensus sequences and secondary
structures of our kanamycin A and tobramycin aptamers, which
20   differ at only two of fourteen bases. As an initial test
for the ability of these aptamers to function *in vivo*, we
asked whether following expression in *E. coli* the aptamer
would sequester the cognate antibiotic thereby conferring a
specific drug-resistant phenotype. Toward this end, one or
25   three copies of the kanamycin A (kan) or the tobramycin
(tob) aptamer were cloned into the T7 RNA polymerase-driven
expression vector pRSETA (Invitrogen), and transformed into
a bacterial strain containing an IPTG-inducible T7 RNA
polymerase. Bacterial strains were grown in liquid culture
30   overnight and then diluted into antibiotic-containing
medium. In the absence of drug, bacterial strains
expressing no aptamer (bl-RSETA), the kanamycin aptamer (bl-
kan1), or the tobramycin aptamer (bl-tob1) grew similarly

- 16 -

(Fig. 3A). In the presence of 10mM kanamycin A, bl-kanl
grew to saturation, whereas growth of bl-RSETA and bl-tobl
was neglible (Fig. 3B). In the presence of 10 mM
tobramycin, bl-tobl grew to saturation, and bl-kanl also
5   grew to a sub-saturating level (Figure 3C). The partial-
resistance of bl-kanl to tobramycin (our unpublished data).
Figures 3D and 3E show that increasing the number of
aptamers in the expression vector from one to three,
enhanced growth in the presence of antibiotic. None of the
10   strains exhibited increased resistance to unrelated
antibiotics. Collectively, these results indicate that a
specific drug-resistant phenotype can be conferred by
expression of an aminoglycoside aptamer, demonstrating the
occurrence and specificity of a small molecule-aptamer
15   interaction *in vivo*.

Based upon the *in vitro* results, we next designed
experiments to investigate whether small molecule aptamers
could be used to regulate gene expression *in vivo*. We
designed these experiments in view of the fact that
20   eukaryotic translation initiation typically involves
5'-to-3' scanning from the 5'-m^{7}G cap to the start codon
(Kozak, *Ann. Rev. Cell Biol.* **8**:197 (1992); Sachs et al.,
Cell **89**:831 (1997)), and binding of a protein between the
cap and start codon can repress translation, presumably by
25   blocking either scanning or the ribosome-mRNA interaction
(Stripecke et al., *Mol. Cell. Biol.* **14**:5898 (1994);
Paraskeva et al., *Proc. Natl. Acad. Sci. USA* **95**:951 (1998)).
These considerations prompted us to test whether the
presence of a small molecule-aptamer complex within the 5'
30   UTR would repress translation in an analogous fashion.

A test mRNA was constructed containing three copies
of the tob aptamer inserted in the 5' UTR of RSETA (tob3-

- 17 -

RSETA). *In vitro* translation reactions were performed in the presence of 0, 30 or 60 μM tobramycin or kanamycin A.

In vitro transcription reactions contained 5 μg pRSETA (or RSET derivative), 0.5 mM m⁷G(5′)G, 0.5 mM ATP,
5   CTP, UTP, 0.05 mM GTP, 10 mM DTT and 40 U T7 RNA polymerase in 50 μl of a solution of 40 mM Tris-HCl pH 7.5, 6 mM MgCl2, 2 mM spermidine, 10 mM NaCl. Following incubation for 1 hour at 37°C, RNA was purified by phenol:chloroform extraction, ethanol precipitation and resuspended in 30 μl
10   H₂O. Translation reactions were carried out in 10 μl containing 5 μl wheat germ extract, 0.8 μl 1 mM amino acid mixture (minus methionine), 2 μl of RNA transcript (described above), 0.5 μl [³⁵S]methionine (1200 Ci/mmole) and 0-80 μM drug. Reactions were incubated at 25°C for 15
15   minutes and terminated by addition of 2X sample loading buffer. Translation products were separated by electrophoresis on an 18% polyacrylamide gel, visualized by autoradiography, and quantitated by densitometry.

Translation of the control RSETA mRNA was unaffected
20   by all concentrations of tobramycin or kanamycin tested. Addition of tobramycin inhibited *in vitro* translation of the tob3-RSETA mRNA in a dose-dependent fashion (Fig. 4). *In vitro* translation of the tob3-RSETA mRNA was not inhibited by comparable concentrations of kanamycin A, which is not
25   recognized by the tob aptamer.

Our results indicated that small molecule-aptamer interactions occur faithfully *in vivo* (Figs. 3A-3E). The results summarized in Fig. 4 showed that in a cell-free system a small molecule can be used to regulate translation
30   through a cis-acting aptamer. We therefore reconfigured the system for regulating gene expression *in vivo*. Because aminoglycosides were known to be relatively impermeable to the plasma membrane, to be cytotoxic, and at elevated

- 18 -

concentrations to have a general inhibitory effect on translation, we elected to use a different cell-permeable small molecule as the translation regulator.

We chose the Hoeschst dye 33258 (H33258) and the
5   closely related drug H33342 (Figs. 5 and 6), because they were known to be relatively non-toxic and cell-permeable (Uphoff et al., *Curr. Opin. Struct. Biol.* **6**:281 (1996)). We isolated RNA aptamers that bound specifically to H33258 by affinity chromatography on a column containing H33258
10 covalently attached to an epoxy-activated sepharose resin through a single hydroxyl group. Figs. 7 and 8 show the sequences and secondary structures of two of these aptamers, H10 and H19, isolated after 10 rounds of selection. H10 and H19 bound to an H33258 affinity-column and required a
15 relatively high concentration (25mM) of free H33258 for elution (Fig. 9). H10 and H19 bound H33258 and the closely related H33342 comparably (data not shown).

To demonstrate that the H33258-aptamer could be used to regulate translation, one copy of H10 and H19 were
20 inserted in tandem into the 5' UTR of RSETA. Addition of H33258 inhibited *in vitro* translation of H2-RSETA, but not the control RSETA, in a dose-dependent fashion (Fig. 10).

To test whether this small molecule-aptamer interaction could be used to control gene expression *in*
25 *vivo*, one copy of H10 and H'9 were inserted into the 5'UTR of a mammalian β-galactosidase expression plasmid SVβGal (Promega), generating the construct SVH2βgal. CHO cells were cotransfected with SVH2βGal or as a control the parental vector, SVβGal, and a luciferase reporter gene to
30 provide an internal control. Following transfection, cells were grown for 24 hours in the presence of 0, 5 or 10 μM H33342 and analyzed for β-galactosidase and luciferase activities. In these experiments, H33342, rather than

H33258, was used because it is approximately ten-fold more
cell-permeable.

In the absence of drug, two H33258 aptamers in the
5'UTR had no effect on gene expression (compare SVβgal and
5   SVH2βgal)(Fig. 11). This was consistent with the *in vitro*
translation data shown in Fig. 10. Expression of the
luciferase reporter (Figure 11) and the parental expression
vector SVβGal (data not shown) were not inhibited by 0,5 or
10 uM H33342. H33342 reduced β-galactosidase activity from
10   SVH2βGal greater than 90% in a dose-dependent fashion.
These results indicated that inhibition by H33342 is
dependent upon the presence of an appropriate RNA aptamer in
the 5'UTR, and that the small molecule-aptamer translation
switch works both *in vitro* and *in vivo*.
15   H33258 aptamers, H10 and H19, were cloned in tandem
into the 5' UTR of a β-galactosidase reporter gene (SVβgal,
Promega) to generate SVH2βgal. CHO cells were cotransfected
with 1 μg SVβgal or SVH2βgal and 1 μg of a luciferase
expression vector (pGL3). Transfected cells were grown in
20   the presence of 0, 5 or 10 mM H33342. 24 hours post-
transfection cell extracts were prepared and β-galactosidase
and luciferase activities were determined.

Other embodiments are within the following claims.